ABSTRACT
Objective To investigate the serum amyloid A (SAA) and interleukin-18(IL-18)concentration in the pathogenesis of type 2 diabetes mellitus (T2DM) and its macrovascular complications, and study the relation between them. Methods ELISA was used to assay serum SAA and IL-18 levels in 65 T2DM patients (including 31 cases with macrovascular complications) and 30 healthy controls. Results Serum SAA and IL-18 levels [(3.09±0.96)mg/L, (98.8±36.4)ng/L]were significantly elevated in patients with T2DM as compared with those in control subjects [(1.06±0.45)mg/L, (58.9±15.6)ng/L](P<0.05). There was significant difference of SAA and IL-18 levels between T2DM patients with [(6.34±1.52) mg/L,(141.2±48.3)ng/L]and without macrovascukar complications [(2.65±0.39)mg/L, (80.2±20.1)ng/L](P < 0.05).Univariate linear regression analysis showed significant positive correlations between serum IL-18 with SAA (r =0.615, P<0.05), SAA, IL-18 and fasting blood glucose (FBG) had mutual positive correlations (r=0.312, 0.428, P< 0.05, respectively). Conclusions In patients with T2DM, serum SAA and IL-18 concentration is greater than in non-diabetic subjects. SAA and IL-18 play important roles in the initiation and development of T2DM. The study suggests that SAA and IL-18 might be an important independent risk factor.
ABSTRACT
Objective To investigate the C-reactive protein (CRP) concentrations in the pathogenesis of type 2 diabetes mellitus (DM) and its macrovascular complications. Methods Serum CRP levels were assayed by ELISA, which were determined in type 2 DM patients with or without macrovascular complication (88 and 64 cases respectively), non-DM patients presenting with macrovascular disease (72 cases), as well as impaired fasting glucose (IFG) (62 cases) or impaired glucose tolerance (IGT) (70 cases) patients and normal controls (80 subjects). Results In general, CRP levels in IGT patients, type 2 DM patients and non-DM patients presenting with macrovascular disease were higher than those of normal controls (P
